Health Optimization Index
Magnesium
- Nick’s assessment
- Favorable
- Research evidence
- A, strong evidence
- Attention
- 34.2 / 100▲ Rising this week
BioHarmony score
Magnesium produces consistent, modest effects across an unusually wide range of endpoints: blood pressure -2.81 mmHg per Argeros 2025, HbA1c -0.73% in T2DM per Asbaghi 2022, sleep onset latency -17 min per Mah 2021, and migraine OR 0.20 per Chiu 2016. Approximately 50% of US adults are deficient.
Read the full report Benefits, risks and practical guidance.
Read Nick’s assessment Why it earned this rating
Magnesium is a 8.5–9.0/10 fit for people with low intake, stress load, poor sleep, blood-pressure concerns, migraines, or glucose issues who want a practical mineral correction, not a single fix for every symptom tied to stress or metabolism. The cleanest evidence anchors are Argeros 2025, which found systolic blood pressure fell 2.81 mmHg overall, and Asbaghi 2022, which found HbA1c improvement in type 2 diabetes trials. Mah 2021 adds useful context: found sleep-onset latency improved in older adults. The practical gap is the same one that shows up across the report: mechanism and early outcomes are more convincing than broad real-world certainty. In practice, Magnesium belongs after the basics, works best when the target is specific, and deserves tracking around benefits, side effects, interactions, and cost before it becomes a standing protocol.
✅ Best for: Adults with confirmed or suspected deficiency (approximately 50% of US population per NHANES). Anyone targeting sleep quality, anxiety reduction, blood pressure support, depression augmentation, migraine prevention, or athletic recovery. Vegetarians, athletes with high sweat losses, PPI users (chronic depletion), elderly users (absorption decline plus polypharmacy), and post-bariatric-surgery populations. Form selection matters: glycinate or ionic for sleep and anxiety; threonate for cognitive applications; malate for daytime energy; topical chloride for acute muscle tension; citrate for general-purpose plus mild constipation relief.
❌ Avoid if: You have advanced chronic kidney disease (eGFR below 30) without nephrologist supervision (oral supplementation can drive hypermagnesemia in renal failure). You have active bowel obstruction (osmotic effect can worsen the obstruction). You have myasthenia gravis (NMJ blockade risk even at low doses). You take chronic high-dose digoxin (hypomagnesemia potentiates toxicity, but supplementation should be physician-monitored). You require strict drug timing for bisphosphonates, tetracyclines, or fluoroquinolones (chelation; separate by 2-3 hours). You expect dramatic single-dose effects (the intervention is a slow nutritional correction, not an acute pharmacological lever for already-replete users).
Share your experience
Your answers are optional and help other readers — they never change my score. How community input works.
One step left: confirm it’s you
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.
Make a 12-month prediction Will it rise or fall in the Index?
Choose a direction and your confidence. Correct predictions earn leaderboard points.
Your prediction is final once submitted. We’ll check it in 12 months. See the leaderboard →